Korean Drug Co., Ltd. (KOSDAQ:014570)
South Korea
· Delayed Price · Currency is KRW 4,230.00
-15.00 (-0.35%)
At close: Apr 28, 2026
Korean Drug Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 62,509 | 73,001 | 81,375 | 79,984 | 74,466 | Upgrade
|
| Other Revenue | -0 | - | -0 | -0 | -0 | Upgrade
|
| Revenue | 62,509 | 73,001 | 81,375 | 79,984 | 74,466 | Upgrade
|
| Revenue Growth (YoY) | -14.37% | -10.29% | 1.74% | 7.41% | 11.49% | Upgrade
|
| Cost of Revenue | 35,908 | 38,600 | 44,025 | 45,467 | 43,400 | Upgrade
|
| Gross Profit | 26,601 | 34,401 | 37,350 | 34,517 | 31,065 | Upgrade
|
| Selling, General & Admin | 18,874 | 24,137 | 18,136 | 19,111 | 18,529 | Upgrade
|
| Amortization of Goodwill & Intangibles | 18.41 | 169.6 | 197.35 | 156.68 | 248.27 | Upgrade
|
| Other Operating Expenses | 494.93 | 677.64 | 724.2 | 662 | 745.93 | Upgrade
|
| Operating Expenses | 19,687 | 30,296 | 30,630 | 20,188 | 19,799 | Upgrade
|
| Operating Income | 6,913 | 4,105 | 6,720 | 14,329 | 11,266 | Upgrade
|
| Interest Expense | -3.88 | -4.24 | -3.02 | -2.1 | -1.53 | Upgrade
|
| Interest & Investment Income | 657.64 | 594.69 | 1,213 | 621.01 | 133.66 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.08 | 3.48 | 1.55 | 84.73 | 98.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 414.91 | 218.47 | 205.88 | 32.88 | 182.37 | Upgrade
|
| EBT Excluding Unusual Items | 7,978 | 4,917 | 8,137 | 15,066 | 11,679 | Upgrade
|
| Gain (Loss) on Sale of Investments | -180.6 | 72.9 | 132.87 | -383.6 | -359.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.31 | 3.56 | -4.78 | 2.81 | 1.13 | Upgrade
|
| Pretax Income | 7,797 | 4,994 | 8,265 | 14,685 | 11,321 | Upgrade
|
| Income Tax Expense | 1,285 | 1,998 | 13,182 | 2,876 | 2,278 | Upgrade
|
| Net Income | 6,512 | 2,995 | -4,917 | 11,809 | 9,042 | Upgrade
|
| Net Income to Common | 6,512 | 2,995 | -4,917 | 11,809 | 9,042 | Upgrade
|
| Net Income Growth | 117.42% | - | - | 30.59% | 22.86% | Upgrade
|
| Shares Outstanding (Basic) | - | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | - | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | - | 0.08% | -0.01% | -1.30% | 0.56% | Upgrade
|
| EPS (Basic) | - | 277.55 | -455.98 | 1095.09 | 827.64 | Upgrade
|
| EPS (Diluted) | - | 277.55 | -455.98 | 1095.09 | 827.64 | Upgrade
|
| EPS Growth | - | - | - | 32.31% | 22.18% | Upgrade
|
| Free Cash Flow | 12,653 | 3,842 | -7,812 | -180.15 | 7,660 | Upgrade
|
| Free Cash Flow Per Share | - | 356.01 | -724.50 | -16.71 | 701.12 | Upgrade
|
| Gross Margin | 42.55% | 47.12% | 45.90% | 43.16% | 41.72% | Upgrade
|
| Operating Margin | 11.06% | 5.62% | 8.26% | 17.91% | 15.13% | Upgrade
|
| Profit Margin | 10.42% | 4.10% | -6.04% | 14.76% | 12.14% | Upgrade
|
| Free Cash Flow Margin | 20.24% | 5.26% | -9.60% | -0.22% | 10.29% | Upgrade
|
| EBITDA | 8,882 | 6,174 | 8,469 | 15,712 | 12,736 | Upgrade
|
| EBITDA Margin | 14.21% | 8.46% | 10.41% | 19.64% | 17.10% | Upgrade
|
| D&A For EBITDA | 1,969 | 2,069 | 1,749 | 1,383 | 1,470 | Upgrade
|
| EBIT | 6,913 | 4,105 | 6,720 | 14,329 | 11,266 | Upgrade
|
| EBIT Margin | 11.06% | 5.62% | 8.26% | 17.91% | 15.13% | Upgrade
|
| Effective Tax Rate | 16.48% | 40.02% | 159.49% | 19.58% | 20.13% | Upgrade
|
| Advertising Expenses | 105.78 | 900.89 | 920.23 | 1,014 | 1,082 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.